We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Congestive Heart Failure Surgical Treatmment With Autologous Stem Cell Therapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00480961
First Posted: June 1, 2007
Last Update Posted: June 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
  Purpose
This research study was designed to test the safety and effectiveness of autologous stem cell graft in the myocardium of patients with refractory Congestive Heart Failure (CHF) with ischemic etiology. Cellular implantation will take place during off-pump revascularization surgery or during an ad hoc procedure using a mini-thoracotomy access.

Condition Intervention Phase
Congestive Heart Failure Procedure: intramiocardiac autograft of autologous stem cells Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies:

Primary Outcome Measures:
  • Primary target: determine the safety of introducing CD 34+ autologous progenitor cells (centrally grafted or mobilized in peripheral blood) in the myocardium of ischemic cardiac disease patients. [ Time Frame: 1 YEAR ]

Secondary Outcome Measures:
  • Secondary target: determine clinical effects of grafted cells on remodeling pathology. [ Time Frame: 1 YEAR ]

Study Start Date: May 2007
Detailed Description:
Primary target: determine the safety of introducing CD 34+ autologous progenitor cells (centrally grafted or mobilized in peripheral blood) in the myocardium of ischemic cardiac disease patients. Secondary target: determine clinical effects of grafted cells on remodeling pathology.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Age >18 y/o
  • CHF with EF > 35%
  • Bilirubinemia, serum transaminase> 2.5 times normal max level
  • Creatininemia > 2.5 times max level
  • NYHA Class > 3
  • Negative pregnancy test (for women in fertile age)

Exclusion criteria

  • Impossibility to harvest the bone marrow
  • Pregnancy or breast-feeding
  • History of malignant neoplasia in the 5-year period before the study (save for in-situ carcinoma of the cervix treated successfully and skin tumors – not melanomas)
  • Incapability or unwillingness to comply with the envisaged treatment protocol, follow-up, or tests.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00480961


Contacts
Contact: cesare scardulla, MD 0912192284 cscardulla@ISMETT.edu

Locations
Italy
Ismett Recruiting
Palermo, PA, Italy, 90127
Principal Investigator: CESARE SCARDULLA, md         
Sponsors and Collaborators
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Investigators
Principal Investigator: CESARE SCARDULLA, md The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
  More Information

ClinicalTrials.gov Identifier: NCT00480961     History of Changes
Other Study ID Numbers: IRRB/00/2006
First Submitted: May 31, 2007
First Posted: June 1, 2007
Last Update Posted: June 1, 2007
Last Verified: May 2007

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases